image
Opening
a new frontier
in pharmacology
Opening a new frontier
in pharmacology
Opening
a new frontier
in pharmacology
A pipeline of breakthrough
pharmacological inhibitors
Signaling Specific inhibitors
of the CB1 (CB1-SSi)
Targeting diseases while protecting physiology
AEF0117 for cannabis-related disorders
AEF0217 for the treatment of cognitive deficits
Aelis Farma’s Mission
Conjugate the scientific breakthrough of CB1-SSi with innovative drug development to provide new specific and safe treatments for CNS diseases with unmet medical needs.
Pier Vincenzo Piazza, CEO
Latest News
AELIS FARMA announces a strategic collaboration and option-license agreement with INDIVIOR for the treatment of cannabis-related disorders
June 2021
+
The European Commission grants €6 million to the ICOD project for the development of AEF0217 (AELIS FARMA) to treat cognitive deficits in Down syndrome
April 2021
+